Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
第一作者:
Nicholas,Kartsonis
第一单位:
Merck Research Laboratories, Merck & Co., Inc., BL 3-4, P.O. Box 4, West Point, PA 19486-0004, USA. nicholas_kartsonis@merck.com
作者:
主题词
抗真菌药(Antifungal Agents);念珠菌属(Candida);念珠菌病(Candidiasis);念珠菌病, 口腔(Candidiasis, Oral);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);数据库, 事实型(Databases, Factual);棘白菌素类(Echinocandins);食管(Esophagus);人类(Humans);脂肽类(Lipopeptides);微生物敏感性试验(Microbial Sensitivity Tests);肽类, 环(Peptides, Cyclic);随机对照试验(主题)(Randomized Controlled Trials as Topic);治疗结果(Treatment Outcome)
DOI
10.1128/AAC.49.9.3616-3623.2005
PMID
16127030
发布时间
2018-12-01
- 浏览24
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文